What is the recommended dosage of ceftazidime (CAZ)/avibactam (AVI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Dosage of Ceftazidime/Avibactam

The standard recommended dosage of ceftazidime/avibactam for adults with normal renal function is 2.5 grams (ceftazidime 2 grams and avibactam 0.5 grams) administered every 8 hours by intravenous infusion over 2 hours. 1

Adult Dosing

  • For adults with creatinine clearance (CrCl) greater than 50 mL/min, administer 2.5 grams (ceftazidime 2 grams and avibactam 0.5 grams) every 8 hours by IV infusion over 2 hours 1
  • For complicated intra-abdominal infections (cIAI), ceftazidime-avibactam should be given concurrently with metronidazole 500 mg IV every 6-8 hours 2, 1
  • For complicated urinary tract infections (cUTI) including pyelonephritis, the same dosage of 2.5 grams every 8 hours is recommended 3, 1
  • For hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), the standard dosage of 2.5 grams every 8 hours is also recommended 1

Pediatric Dosing

  • For children aged 2 years to less than 18 years with estimated glomerular filtration rate (eGFR) greater than 50 mL/min/1.73 m²: 62.5 mg/kg (ceftazidime 50 mg/kg and avibactam 12.5 mg/kg) up to a maximum of 2.5 grams every 8 hours 1
  • For children aged 6 months to less than 2 years: 62.5 mg/kg every 8 hours 1
  • For children aged 3 months to less than 6 months: 50 mg/kg (ceftazidime 40 mg/kg and avibactam 10 mg/kg) every 8 hours 1
  • For infants greater than 28 days to less than 3 months: 37.5 mg/kg (ceftazidime 30 mg/kg and avibactam 7.5 mg/kg) every 8 hours 1
  • For neonates less than or equal to 28 days with gestational age 31 weeks and older: 25 mg/kg (ceftazidime 20 mg/kg and avibactam 5 mg/kg) every 8 hours 1

Dosage Adjustment for Renal Impairment

Renal clearance is the primary elimination pathway for both ceftazidime and avibactam, necessitating dose adjustment in patients with impaired renal function 4:

  • For patients with moderate to severe renal impairment, dose adjustment is required as both drugs are primarily eliminated through the kidneys 4
  • Specific dosage adjustments should be made based on creatinine clearance values 1

Duration of Treatment

  • For complicated intra-abdominal infections: 5-14 days 2, 1
  • For complicated urinary tract infections: 7-14 days 2, 1
  • For hospital-acquired and ventilator-associated bacterial pneumonia: 7-14 days 1
  • For bloodstream infections: 7-14 days 2

Special Considerations

  • The fixed-dose combination ratio of ceftazidime to avibactam is 4:1, which aligns with their complementary pharmacokinetic profiles 4
  • Both drugs have a half-life of approximately 2 hours, making the every 8-hour dosing interval appropriate 4
  • For treatment of carbapenem-resistant Enterobacterales (CRE) infections, ceftazidime-avibactam is recommended as a treatment option 3, 2
  • For CRE urinary tract infections specifically, ceftazidime-avibactam 2.5 g IV every 8 hours is recommended 3

Pharmacokinetic/Pharmacodynamic Considerations

  • The target pharmacodynamic indices for efficacy are 50% time above MIC for free ceftazidime and 50% time above threshold concentration of 1 mg/L for free avibactam 4
  • Recent studies suggest that extended infusion times may optimize treatment efficacy, especially for severe infections 5
  • For severe infections in patients with normal renal function or augmented renal clearance, extending the infusion duration to 3-4 hours may be beneficial to achieve higher PK/PD targets 5

Potential Resistance Concerns

  • Emergence of ceftazidime-avibactam resistance in carbapenemase-producing K. pneumoniae has been reported, particularly with prior administration of the drug 3
  • Risk factors for resistance development include mutations in the bla KPC-3 gene 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.